The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. (Q51381364)
Jump to navigation
Jump to search
scientific article published on 19 January 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. |
scientific article published on 19 January 2011 |
Statements
1 reference
The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. (English)
1 reference
G E Umpierrez
1 reference
T Blevins
1 reference
J Rosenstock
1 reference
C Cheng
1 reference
J H Anderson
1 reference
E J Bastyr
1 reference
EGO Study Group
1 reference
19 January 2011
1 reference
13
1 reference
418-425
1 reference
5
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference